L
6.29
0.02 (0.32%)
| Penutupan Terdahulu | 6.27 |
| Buka | 6.22 |
| Jumlah Dagangan | 649,556 |
| Purata Dagangan (3B) | 1,242,656 |
| Modal Pasaran | 459,090,304 |
| Harga / Buku (P/B) | 3.47 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Mar 2026 |
| EPS Cair (TTM) | -3.31 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.67% |
| Nisbah Semasa (MRQ) | 3.41 |
| Aliran Tunai Operasi (OCF TTM) | -88.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -50.43 M |
| Pulangan Atas Aset (ROA TTM) | -42.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -80.65% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Lexeo Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
-1.1
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -3.5 |
| Purata | -1.13 |
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.75% |
| % Dimiliki oleh Institusi | 121.45% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 17.00 (Chardan Capital, 170.27%) | Beli |
| Median | 13.50 (114.63%) | |
| Rendah | 10.00 (HC Wainwright & Co., 58.98%) | Beli |
| Purata | 13.50 (114.63%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 7.43 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 13 Jan 2026 | 17.00 (170.27%) | Beli | 7.43 |
| HC Wainwright & Co. | 13 Jan 2026 | 10.00 (58.98%) | Beli | 7.43 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |